Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Glioma Diagnosis and Treatment, MicroRNA in disease regulation, and Acute Myeloid Leukemia Research.
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study.
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.
Multi-Omics Applications in Adult Acute Lymphoblastic Leukemia: From Biological Mechanisms to Precision Therapies.
Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.
CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues.
Harnessing Venetoclax in NPM1-Mutated AML: A Path to Sustained Remission and Beyond.
The Evolving Role of Hematopoietic Stem Cell Transplantation in Philadelphia-like Acute Lymphoblastic Leukemia: From High-Risk Standard to Precision Strategies.
SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma.
Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis.
Is There a Better Therapeutic Time Window from Diagnosis to Treatment for Elderly Acute Myeloid Leukemia Patients Receiving Hypomethylating Agents?
Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.
A year in review in Minerva Anestesiologica 2023: anesthesia, analgesia, and perioperative medicine
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Sustained Remission in an Elderly Patient with Acute Myeloid Leukemia Following Gilteritinib Treatment as Third-Line Salvage Therapy.
Epcoritamab in B-cell malignancies: current status and prospects.
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat <i>FLT3</i>-Mutated AML Patients.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.
Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
TP53 mutations in therapy-related acute myeloid leukemia: still the dark side of the moon?
Immunotherapy of Acute Myeloid Leukemia: A Work in Progress
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML Patients
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology.
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report.
Enlarging the clinical spectrum of chorea-acanthocytosis.